{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:21:03Z","timestamp":1787458863409,"version":"build-2736575974"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04299-4","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:13:55Z","timestamp":1774088035000},"page":"3632-3650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities"],"prefix":"10.1007","volume":"28","author":[{"given":"Jinpeng","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6302-9287","authenticated-orcid":false,"given":"Changhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"issue":"3","key":"4299_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA: Cancer J Clin"},{"issue":"11","key":"4299_CR2","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.3390\/ijms26115173","volume":"26","author":"A Forma","year":"2025","unstructured":"Forma A, K\u0142odnicka K, Paj\u0105k W, Flieger J, Teresi\u0144ska B, Januszewski J, et al. Thyroid cancer: epidemiology, classification, risk factors, diagnostic and prognostic markers, and current treatment strategies. Int J Mole Sci. 2025;26(11):5173.","journal-title":"Int J Mole Sci"},{"key":"4299_CR3","doi-asserted-by":"publisher","DOI":"10.1530\/erc-22-0293","author":"CC Juhlin","year":"2023","unstructured":"Juhlin CC, Mete O, Baloch ZW. The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr Relat Cancer. 2023. https:\/\/doi.org\/10.1530\/erc-22-0293.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"4299_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"issue":"3","key":"4299_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin."},{"key":"4299_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15111438","author":"J Mihailovi\u0107","year":"2025","unstructured":"Mihailovi\u0107 J. Evolving paradigm in radioactive iodine therapy for differentiated thyroid cancer: historical perspectives, current practices and future directions. Diagnostics (Basel). 2025. https:\/\/doi.org\/10.3390\/diagnostics15111438.","journal-title":"Diagnostics (Basel)."},{"key":"4299_CR7","doi-asserted-by":"publisher","DOI":"10.1530\/etj-24-0371","author":"NS Huang","year":"2025","unstructured":"Huang NS, Chen JY, Wei WJ, Hu JQ, Wang YJ, Liu WL, et al. Personalized treatment of 95 poorly differentiated thyroid cancer\/anaplastic thyroid cancer in 2019\u20132023. Eur Thyroid J. 2025. https:\/\/doi.org\/10.1530\/etj-24-0371.","journal-title":"Eur Thyroid J."},{"key":"4299_CR8","unstructured":"Ramos Santillan V, Master SR, Menon G, Burns B. Medullary thyroid cancer. StatPearls. Treasure Island (FL) with ineligible companies. Disclosure: Samip Master declares no relevant financial relationships with ineligible companies. Disclosure: Gopal Menon declares no relevant financial relationships with ineligible companies. Disclosure: Bracken Burns declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"1","key":"4299_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41232-025-00398-x","volume":"45","author":"E Khodabandehloo","year":"2025","unstructured":"Khodabandehloo E, Rayati M, Ahmadi E, Naghdibadi M, Moradi V, Ahmadbeigi N. Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors. Inflamm Regen. 2025;45(1):34. https:\/\/doi.org\/10.1186\/s41232-025-00398-x.","journal-title":"Inflamm Regen."},{"key":"4299_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.929091","volume":"13","author":"A Garcia-Alvarez","year":"2022","unstructured":"Garcia-Alvarez A, Hernando J, Carmona-Alonso A, Capdevila J. What is the status of immunotherapy in thyroid neoplasms? Front Endocrinol (Lausanne). 2022;13:929091. https:\/\/doi.org\/10.3389\/fendo.2022.929091.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"4299_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12672-024-00904-6","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang Y, Xing Y, Wang H, He M, Guo R. Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials. Discov Oncol. 2024;15(1):50. https:\/\/doi.org\/10.1007\/s12672-024-00904-6.","journal-title":"Discov Oncol."},{"key":"4299_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.637826","volume":"11","author":"E Menicali","year":"2020","unstructured":"Menicali E, Guzzetti M, Morelli S, Moretti S, Puxeddu E. Immune Landscape of Thyroid Cancers: New Insights. Front Endocrinol (Lausanne). 2020;11:637826. https:\/\/doi.org\/10.3389\/fendo.2020.637826.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"4299_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1089\/thy.2011.0452","volume":"22","author":"W Qing","year":"2012","unstructured":"Qing W, Fang W-Y, Ye L, Shen L-Y, Zhang X-F, Fei X-C, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid. 2012;22(9):905\u201310.","journal-title":"Thyroid."},{"issue":"8","key":"4299_CR14","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/carcin\/bgu060","volume":"35","author":"W Fang","year":"2014","unstructured":"Fang W, Ye L, Shen L, Cai J, Huang F, Wei Q, et al. Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis. 2014;35(8):1780\u20137.","journal-title":"Carcinogenesis."},{"issue":"4","key":"4299_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","volume":"49","author":"KY Jung","year":"2015","unstructured":"Jung KY, Cho SW, Kim YA, Kim D, Oh B-C, Park DJ, et al. Cancers with higher density of tumor-associated macrophages were associated with poor survival rates. J Pathol Trans Med. 2015;49(4):318\u201324.","journal-title":"J Pathol Trans Med"},{"issue":"1","key":"4299_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054302","volume":"8","author":"M Ryder","year":"2013","unstructured":"Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, et al. Genetic and pharmacological targeting of CSF-1\/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013;8(1):e54302. https:\/\/doi.org\/10.1371\/journal.pone.0054302.","journal-title":"PLoS One."},{"key":"4299_CR17","doi-asserted-by":"publisher","first-page":"F1000 Faculty R","DOI":"10.12688\/f1000research.16677.1","volume":"8","author":"F Liotti","year":"2019","unstructured":"Liotti F, Prevete N, Vecchio G, Melillo RM. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. F1000Research. 2019;8:F1000 Faculty Rev-227.","journal-title":"F1000Research."},{"issue":"1","key":"4299_CR18","doi-asserted-by":"publisher","first-page":"18125","DOI":"10.1038\/s41598-024-69187-9","volume":"14","author":"X Li","year":"2024","unstructured":"Li X, Jian J, Zhang A, Xiang JM, Huang J, Chen Y. The role of immune cells and immune related genes in the tumor microenvironment of papillary thyroid cancer and their significance for immunotherapy. Sci Rep. 2024;14(1):18125. https:\/\/doi.org\/10.1038\/s41598-024-69187-9.","journal-title":"Sci Rep."},{"issue":"47","key":"4299_CR19","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1038\/onc.2010.348","volume":"29","author":"R Melillo","year":"2010","unstructured":"Melillo R, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, et al. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29(47):6203\u201315.","journal-title":"Oncogene."},{"issue":"40","key":"4299_CR20","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1038\/onc.2014.441","volume":"34","author":"C Visciano","year":"2015","unstructured":"Visciano C, Liotti F, Prevete N, Cali G, Franco R, Collina F, et al. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8\u2013Akt\u2013Slug pathway. Oncogene. 2015;34(40):5175\u201386.","journal-title":"Oncogene."},{"issue":"11","key":"4299_CR21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1089\/thy.2011.0059","volume":"21","author":"A Proietti","year":"2011","unstructured":"Proietti A, Ugolini C, Melillo RM, Crisman G, Elisei R, Santoro M, et al. Higher intratumoral expression of CD1a, Tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid\u00ae. 2011;21(11):1209\u201315. https:\/\/doi.org\/10.1089\/thy.2011.0059.","journal-title":"Thyroid\u00ae"},{"issue":"8","key":"4299_CR22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neo.2015.08.002","volume":"17","author":"P Minder","year":"2015","unstructured":"Minder P, Zajac E, Quigley JP, Deryugina EI. EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia. 2015;17(8):634\u201349.","journal-title":"Neoplasia."},{"issue":"1","key":"4299_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-018-1003-0","volume":"38","author":"S Li","year":"2019","unstructured":"Li S, Cong X, Gao H, Lan X, Li Z, Wang W, et al. Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells. J Exp Clin Cancer Res. 2019;38(1):6.","journal-title":"J Exp Clin Cancer Res."},{"key":"4299_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3389\/fimmu.2019.01690","volume":"10","author":"H-H Oberg","year":"2019","unstructured":"Oberg H-H, Wesch D, Kalyan S, Kabelitz D. Regulatory interactions between neutrophils, tumor cells and T cells. Front Immunol. 2019;10:1690.","journal-title":"Front Immunol."},{"issue":"1","key":"4299_CR25","first-page":"8471235","volume":"2017","author":"DK Manatakis","year":"2017","unstructured":"Manatakis DK, Tseleni-Balafouta S, Balalis D, Soulou VN, Korkolis DP, Sakorafas GH, et al. Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma. Int J Endocrinol. 2017;2017(1):8471235.","journal-title":"Int J Endocrinol."},{"issue":"20","key":"4299_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019686","volume":"99","author":"J Feng","year":"2020","unstructured":"Feng J, Wang Y, Shan G, Gao L. Clinical and prognostic value of neutrophil-lymphocyte ratio for patients with thyroid cancer: A meta-analysis. Medicine. 2020;99(20):e19686.","journal-title":"Medicine."},{"issue":"1","key":"4299_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12020-023-03340-8","volume":"81","author":"N Treistman","year":"2023","unstructured":"Treistman N, Cavalcante LBCP, Gonzalez F, Fernandes PIW, de Andrade FA, Garcis Alves-Junior PA, et al. Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients. Endocrine. 2023;81(1):141\u20138.","journal-title":"Endocrine."},{"issue":"5","key":"4299_CR28","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.21873\/invivo.12113","volume":"34","author":"N Fukuda","year":"2020","unstructured":"Fukuda N, Toda K, Fujiwara Y, Wang X, Ohmoto A, Urasaki T, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib. In vivo. 2020;34(5):2859\u201364.","journal-title":"In vivo."},{"issue":"6","key":"4299_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199740","volume":"13","author":"MR Galdiero","year":"2018","unstructured":"Galdiero MR, Varricchi G, Loffredo S, Bellevicine C, Lansione T, Ferrara AL, et al. Potential involvement of neutrophils in human thyroid cancer. PLoS One. 2018;13(6):e0199740.","journal-title":"PLoS One."},{"issue":"8","key":"4299_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","volume":"15","author":"L Co\u00ebnon","year":"2024","unstructured":"Co\u00ebnon L, Geindreau M, Ghiringhelli F, Villalba M, Bruchard M. Natural Killer cells at the frontline in the fight against cancer. Cell Death Dis. 2024;15(8):614. https:\/\/doi.org\/10.1038\/s41419-024-06976-0.","journal-title":"Cell Death Dis."},{"key":"4299_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.intimp.2018.09.016","volume":"64","author":"M Yin","year":"2018","unstructured":"Yin M, Di G, Bian M. Dysfunction of natural killer cells mediated by PD-1 and Tim-3 pathway in anaplastic thyroid cancer. Int Immunopharmacol. 2018;64:333\u20139. https:\/\/doi.org\/10.1016\/j.intimp.2018.09.016.","journal-title":"Int Immunopharmacol."},{"issue":"6","key":"4299_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/j.1365-2265.2012.04482.x","volume":"77","author":"LL Cunha","year":"2012","unstructured":"Cunha LL, Morari EC, Guihen AC, Razolli D, Gerhard R, Nonogaki S, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol. 2012;77(6):918\u201325.","journal-title":"Clin Endocrinol."},{"key":"4299_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.931647","volume":"13","author":"S Banerjee","year":"2022","unstructured":"Banerjee S, Nahar U, Dahiya D, Mukherjee S, Dey P, Gupta R, et al. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2022;13:931647. https:\/\/doi.org\/10.3389\/fendo.2022.931647.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"4299_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/cen.12586","volume":"83","author":"LL Cunha","year":"2015","unstructured":"Cunha LL, Marcello MA, Nonogaki S, Morari EC, Soares FA, Vassallo J, et al. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2015;83(2):246\u201353. https:\/\/doi.org\/10.1111\/cen.12586.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"9","key":"4299_CR35","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1089\/thy.2014.0134","volume":"24","author":"TE Angell","year":"2014","unstructured":"Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014;24(9):1385\u201393. https:\/\/doi.org\/10.1089\/thy.2014.0134.","journal-title":"Thyroid."},{"key":"4299_CR36","doi-asserted-by":"publisher","DOI":"10.1530\/erc-24-0169","author":"X Ruan","year":"2025","unstructured":"Ruan X, Tao M, Dong Y, Hu L, Xu G, Hu C, et al. Persistent pre-exhausted CD8+ T cells shape the tumor immune microenvironment in anaplastic thyroid cancer. Endocr Relat Cancer. 2025. https:\/\/doi.org\/10.1530\/erc-24-0169.","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"4299_CR37","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/jc.2009-2564","volume":"95","author":"JD French","year":"2010","unstructured":"French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95(5):2325\u201333. https:\/\/doi.org\/10.1210\/jc.2009-2564.","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"4299_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s12094-014-1222-6","volume":"17","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yun X, Gao M, Yu Y, Li X. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto\u2019s thyroiditis. Clin Transl Oncol. 2015;17(4):274\u201380. https:\/\/doi.org\/10.1007\/s12094-014-1222-6.","journal-title":"Clin Transl Oncol."},{"key":"4299_CR39","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-23-0240","author":"S Li","year":"2024","unstructured":"Li S, Chen Z, Liu M, Li L, Cai W, Lian Z-X, et al. Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma. Endocrine-Related Cancer. 2024. https:\/\/doi.org\/10.1530\/ERC-23-0240.","journal-title":"Endocrine-Related Cancer."},{"issue":"1","key":"4299_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320. https:\/\/doi.org\/10.1038\/s41392-023-01522-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4299_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/ol.2021.12814","volume":"22","author":"S Cameselle-Garc\u00eda","year":"2021","unstructured":"Cameselle-Garc\u00eda S, Abdulkader-Sande S, S\u00e1nchez-Ares M, Rodr\u00edguez-Carnero G, Garcia-G\u00f3mez J, Gude-Sampedro F, et al. PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study. Oncol Lett. 2021;22(1):553. https:\/\/doi.org\/10.3892\/ol.2021.12814.","journal-title":"Oncol Lett."},{"issue":"2","key":"4299_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"S Ahn","year":"2017","unstructured":"Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24(2):97\u2013106.","journal-title":"Endocr Relat Cancer."},{"key":"4299_CR43","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.2147\/CMAR.S392475","volume":"14","author":"AS Harahap","year":"2022","unstructured":"Harahap AS, Lay FK, Kodariah R, Wongkar FJ, Ham MF. Association of programmed death-ligand 1 expression with aggressive histological types of thyroid carcinoma. Cancer Manage Res. 2022;14:3539\u201350.","journal-title":"Cancer Manage Res."},{"issue":"3","key":"4299_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.pathol.2019.11.007","volume":"52","author":"M Fadia","year":"2020","unstructured":"Fadia M, Fookeerah P, Ali S, Shadbolt B, Greenaway T, Perampalam S. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study. Pathology. 2020;52(3):318\u201322.","journal-title":"Pathology."},{"key":"4299_CR45","doi-asserted-by":"publisher","first-page":"1643421","DOI":"10.3389\/fimmu.2025.1643421","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Gao S, Shan C, Zhang Q, Tan Y, Yu X, et al. Advances in PD-1\/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives. Front Immunol. 2025;16:1643421.","journal-title":"Front Immunol"},{"key":"4299_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103042","volume":"141","author":"J Tasong","year":"2025","unstructured":"Tasong J, Sheldon R, Clements A, Abid MT, Gan A. Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review. Cancer Treat Rev. 2025;141:103042. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103042.","journal-title":"Cancer Treat Rev."},{"issue":"8","key":"4299_CR47","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cncr.34657","volume":"129","author":"D-Y Oh","year":"2023","unstructured":"Oh D-Y, Algazi A, Capdevila J, Longo F, Miller W Jr, Chun Bing JT, et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. Cancer. 2023;129(8):1195\u2013204. https:\/\/doi.org\/10.1002\/cncr.34657.","journal-title":"Cancer."},{"issue":"23","key":"4299_CR48","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/jco.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020;38(23):2620\u20137. https:\/\/doi.org\/10.1200\/jco.19.02727.","journal-title":"J Clin Oncol."},{"key":"4299_CR49","doi-asserted-by":"publisher","first-page":"1680838","DOI":"10.3389\/fimmu.2025.1680838","volume":"16","author":"J Park","year":"2025","unstructured":"Park J, Sk\u00e5lhegg BS. Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer - a brief update. Front Immunol. 2025;16:1680838. https:\/\/doi.org\/10.3389\/fimmu.2025.1680838.","journal-title":"Front Immunol."},{"issue":"1","key":"4299_CR50","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1038\/s41467-025-60657-w","volume":"16","author":"I Damei","year":"2025","unstructured":"Damei I, Caidi A, Auclin E, Adam J, Mella S, Hasan M, et al. Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies. Nature Communications. 2025;16(1):5588. https:\/\/doi.org\/10.1038\/s41467-025-60657-w.","journal-title":"Nature Communications."},{"issue":"15_suppl","key":"4299_CR51","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","volume":"38","author":"JH Lorch","year":"2020","unstructured":"Lorch JH, Barletta JA, Nehs M, Uppaluri R, Alexander EK, Haddad RI, et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J Clin Oncol. 2020;38(15_suppl):6513.","journal-title":"J Clin Oncol."},{"issue":"12","key":"4299_CR52","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2024.4019","volume":"10","author":"K Sehgal","year":"2024","unstructured":"Sehgal K, Pappa T, Shin KY, Schiantarelli J, Liu M, Ricker C, et al. Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2024;10(12):1663\u201371. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4019.","journal-title":"JAMA Oncol."},{"key":"4299_CR53","doi-asserted-by":"publisher","first-page":"1554499","DOI":"10.3389\/fimmu.2025.1554499","volume":"16","author":"J Jiang","year":"2025","unstructured":"Jiang J, Li H, Ma Q, Liu J, Ren F, Song Y, et al. Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application. Front Immunol. 2025;16:1554499. https:\/\/doi.org\/10.3389\/fimmu.2025.1554499.","journal-title":"Front Immunol."},{"issue":"16_suppl","key":"4299_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e18070","volume":"42","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman BM, et al. Atezolizumab plus taxane chemotherapy for the treatment of non-BRAF, non-RAS mutated anaplastic thyroid carcinoma: Final analysis. J Clin Oncol. 2024;42(16_suppl):e18070.","journal-title":"J Clin Oncol."},{"issue":"6","key":"4299_CR55","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1078-0432.Ccr-16-1432","volume":"23","author":"C Tang","year":"2017","unstructured":"Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23(6):1388\u201396. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1432.","journal-title":"Clin Cancer Res."},{"issue":"7","key":"4299_CR56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1089\/thy.2022.0050","volume":"32","author":"NY Lee","year":"2022","unstructured":"Lee NY, Riaz N, Wu V, Brinkman T, Tsai CJ, Zhi W, et al. A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image-guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer. Thyroid. 2022;32(7):799\u2013806. https:\/\/doi.org\/10.1089\/thy.2022.0050.","journal-title":"Thyroid."},{"key":"4299_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092279","author":"N Fukuda","year":"2021","unstructured":"Fukuda N, Takahashi S. Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092279.","journal-title":"Cancers (Basel)."},{"key":"4299_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/btt.S57619","volume":"8","author":"S Jasim","year":"2014","unstructured":"Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics. 2014;8:281\u201391. https:\/\/doi.org\/10.2147\/btt.S57619.","journal-title":"Biologics."},{"issue":"12","key":"4299_CR59","doi-asserted-by":"publisher","first-page":"7172","DOI":"10.1245\/s10434-023-14031-z","volume":"30","author":"JY Chen","year":"2023","unstructured":"Chen JY, Huang NS, Wei WJ, Hu JQ, Cao YM, Shen Q, et al. The efficacy and safety of surufatinib combined with anti PD-1 antibody toripalimab in neoadjuvant treatment of locally advanced differentiated thyroid cancer: a phase II study. Ann Surg Oncol. 2023;30(12):7172\u201380. https:\/\/doi.org\/10.1245\/s10434-023-14031-z.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"4299_CR60","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","volume":"10","author":"ME Cabanillas","year":"2024","unstructured":"Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, et al. Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: a nonrandomized clinical trial. JAMA Oncol. 2024;10(12):1672\u201380. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4729.","journal-title":"JAMA Oncol."},{"issue":"16_suppl","key":"4299_CR61","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1200\/JCO.2022.40.16_suppl.6085","volume":"40","author":"D Ji","year":"2022","unstructured":"Ji D, Shen W, Kuang M, Liu Y, Li H, Wang Y, et al. A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer. J Clin Oncol. 2022;40(16_suppl):6085.","journal-title":"J Clin Oncol."},{"issue":"3","key":"4299_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, et al. Checkpoint Inhibition in Addition to Dabrafenib\/Trametinib for BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024;34(3):336\u201346. https:\/\/doi.org\/10.1089\/thy.2023.0573.","journal-title":"Thyroid."},{"key":"4299_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115888","volume":"169","author":"V Moradi","year":"2023","unstructured":"Moradi V, Omidkhoda A, Ahmadbeigi N. The paths and challenges of \u201coff-the-shelf\u201d CAR-T cell therapy: An overview of clinical trials. Biomed Pharmacother. 2023;169:115888. https:\/\/doi.org\/10.1016\/j.biopha.2023.115888.","journal-title":"Biomed Pharmacother."},{"issue":"1","key":"4299_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther."},{"issue":"24","key":"4299_CR65","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1158\/1078-0432.Ccr-17-2008","volume":"23","author":"IM Min","year":"2017","unstructured":"Min IM, Shevlin E, Vedvyas Y, Zaman M, Wyrwas B, Scognamiglio T, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin Cancer Res. 2017;23(24):7569\u201383. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2008.","journal-title":"Clin Cancer Res."},{"issue":"8_supplement_2","key":"4299_CR66","doi-asserted-by":"publisher","first-page":"CT206-CT","DOI":"10.1158\/1538-7445.AM2025-CT206","volume":"85","author":"SA Srour","year":"2025","unstructured":"Srour SA, Lorch JH, Zafereo ME, Villaflor VM, Xing Y, Gupta S, et al. Abstract CT206: ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the phase 1 dose escalation study. Cancer Res. 2025;85(8_supplement_2):CT206-CT.","journal-title":"Cancer Res."},{"issue":"1","key":"4299_CR67","doi-asserted-by":"publisher","first-page":"10634","DOI":"10.1038\/s41598-019-46938-7","volume":"9","author":"Y Vedvyas","year":"2019","unstructured":"Vedvyas Y, McCloskey JE, Yang Y, Min IM, Fahey TJ, Zarnegar R, et al. Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci Rep. 2019;9(1):10634. https:\/\/doi.org\/10.1038\/s41598-019-46938-7.","journal-title":"Sci Rep."},{"issue":"4","key":"4299_CR68","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1210\/clinem\/dgab819","volume":"107","author":"H Li","year":"2022","unstructured":"Li H, Zhou X, Wang G, Hua D, Li S, Xu T, et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107(4):1110\u201326. https:\/\/doi.org\/10.1210\/clinem\/dgab819.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"4299_CR69","doi-asserted-by":"publisher","first-page":"R191","DOI":"10.1530\/ERC-17-0010","volume":"24","author":"CW Rowe","year":"2017","unstructured":"Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, et al. Targeting the TSH receptor in thyroid cancer. Endocrine-Related Cancer. 2017;24(6):R191\u2013202. https:\/\/doi.org\/10.1530\/ERC-17-0010.","journal-title":"Endocrine-Related Cancer."},{"issue":"46","key":"4299_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202513243","volume":"12","author":"F Wang","year":"2025","unstructured":"Wang F, Zuo H, Liu L, Wang S, Zhao H, Liu Z, et al. TSH ligand-based CAR-T cell effectively eradicates TSHR-positive thyroid cancer with favorable safety profile. Adv Sci. 2025;12(46):e13243. https:\/\/doi.org\/10.1002\/advs.202513243.","journal-title":"Adv Sci."},{"key":"4299_CR71","doi-asserted-by":"publisher","DOI":"10.1530\/etj-24-0369","author":"S Xu","year":"2025","unstructured":"Xu S, Peng Y, Li X, Li H, Liu T, Li X, et al. TSHR in thyroid cancer: bridging biological insights to targeted strategies. Eur Thyroid J. 2025. https:\/\/doi.org\/10.1530\/etj-24-0369.","journal-title":"Eur Thyroid J."},{"key":"4299_CR72","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1016\/j.jcyt.2024.03.361","volume":"26","author":"C Manriquez Roman","year":"2024","unstructured":"Manriquez Roman C, Siegler E, Demirer A, Pawlush M, Huynh TN, Mai LK, et al. Optimization of TSHR-cart cell therapy to translate into a first in human phase I clinical trial in metastatic thyroid cancers. Cytotherapy. 2024;26:S182\u20133. https:\/\/doi.org\/10.1016\/j.jcyt.2024.03.361.","journal-title":"Cytotherapy."},{"issue":"14_Supplement","key":"4299_CR73","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1158\/1538-7445.AM2016-2295","volume":"76","author":"VG Bhoj","year":"2016","unstructured":"Bhoj VG, Nunez-Cruz S, Zhou K, Arhontoulis D, Feldman M, Mansfield K, et al. Abstract 2295: GDNF family receptor alpha 4 (GFRa4)-targeted adoptive T-cell immunotherapy for medullary thyroid carcinoma. Cancer Res. 2016;76(14_Supplement):2295.","journal-title":"Cancer Res."},{"key":"4299_CR74","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.omto.2021.01.012","volume":"20","author":"VG Bhoj","year":"2021","unstructured":"Bhoj VG, Li L, Parvathaneni K, Zhang Z, Kacir S, Arhontoulis D, et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol Ther Oncolytics. 2021;20:387\u201398. https:\/\/doi.org\/10.1016\/j.omto.2021.01.012.","journal-title":"Mol Ther Oncolytics."},{"key":"4299_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0290","author":"Y Mann","year":"2024","unstructured":"Mann Y, Majdoul S, Mirazee J, Fierra Pineda JC, Pouzolles M, Chien C, et al. 290 Development of novel anti-GFR\u03b14 chimeric antigen receptor T cells for the treatment of medullary thyroid carcinoma. J ImmunoTher Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0290.","journal-title":"J ImmunoTher Cancer."},{"issue":"1","key":"4299_CR76","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13000-024-01504-2","volume":"19","author":"P Song","year":"2024","unstructured":"Song P, Xu Y, Ye G. B7\u2013H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma. Diagn Pathol. 2024;19(1):77. https:\/\/doi.org\/10.1186\/s13000-024-01504-2.","journal-title":"Diagn Pathol."},{"key":"4299_CR77","doi-asserted-by":"publisher","first-page":"1517525","DOI":"10.3389\/fendo.2025.1517525","volume":"16","author":"F Wang","year":"2025","unstructured":"Wang F, Zhang R, Zhou Z, Shi R, Peng F, Xu Y, et al. CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies. Front Endocrinol. 2025;16:1517525. https:\/\/doi.org\/10.3389\/fendo.2025.1517525.","journal-title":"Front Endocrinol."},{"key":"4299_CR78","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Jiang C, Liu Z, Yang M, Tang X, Wang Y, et al. B7\u2013H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180\u20139. https:\/\/doi.org\/10.1016\/j.omto.2020.03.019.","journal-title":"Mol Ther Oncolytics."},{"issue":"1","key":"4299_CR79","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-025-03475-8","volume":"44","author":"G Cattaneo","year":"2025","unstructured":"Cattaneo G, Ventin M, Arya S, Bailey C, Vantaku VR, Jia J, et al. B7\u2013H3 and CSPG4-targeted CAR T cells as potent effectors in anaplastic thyroid cancer. J Exp Clin Cancer Res. 2025;44(1):248. https:\/\/doi.org\/10.1186\/s13046-025-03475-8.","journal-title":"J Exp Clin Cancer Res."},{"issue":"8","key":"4299_CR80","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.7150\/jca.30163","volume":"10","author":"H Duan","year":"2019","unstructured":"Duan H, Huang H, Jing G. An antibody fab fragment-based chimeric antigen receptor could efficiently eliminate human thyroid cancer cells. J Cancer. 2019;10(8):1890\u20135. https:\/\/doi.org\/10.7150\/jca.30163.","journal-title":"J Cancer."},{"key":"4299_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0239","author":"G Cattaneo","year":"2023","unstructured":"Cattaneo G, Ventin M, Vantaku VR, Arya S, Jia J, Maggs L, et al. 239 CSPG4-targeted CAR T cells demonstrate potent antitumor activity in an orthotopic murine model of anaplastic thyroid cancer. J ImmunoTher Cancer. 2023. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.0239.","journal-title":"J ImmunoTher Cancer."},{"issue":"12","key":"4299_CR82","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/ct.2021;33.539-540","volume":"33","author":"JH Lorch","year":"2021","unstructured":"Lorch JH. CSPG4 is a potential therapeutic target in anaplastic thyroid cancer. Clin Thyroidol\u00ae. 2021;33(12):539\u201340. https:\/\/doi.org\/10.1089\/ct.2021;33.539-540.","journal-title":"Clin Thyroidol\u00ae."},{"issue":"14","key":"4299_CR83","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3390\/cells14141087","volume":"14","author":"K Prakash","year":"2025","unstructured":"Prakash K, Rajendran RL, Dhayalan S, Gangadaran P, Ahn B-C, Aruljothi KN. Natural killer cell and extracellular vesicle-based immunotherapy in thyroid cancer: advances, challenges, and future perspectives. Cells. 2025;14(14):1087.","journal-title":"Cells."},{"issue":"7","key":"4299_CR84","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1089\/thy.2022.0020","volume":"32","author":"TA Erickson","year":"2022","unstructured":"Erickson TA, Shih YP, Fass J, Jang M, Tran E. T Cells engineered to express immunoreceptors targeting the frequently expressed medullary thyroid cancer antigens calcitonin, CEA, and RET M918T. Thyroid. 2022;32(7):789\u201398. https:\/\/doi.org\/10.1089\/thy.2022.0020.","journal-title":"Thyroid."},{"key":"4299_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK. Recent Advances in IL-13R\u03b12-Directed Cancer Immunotherapy. Front Immunol. 2022;13:878365. https:\/\/doi.org\/10.3389\/fimmu.2022.878365.","journal-title":"Front Immunol."},{"key":"4299_CR86","unstructured":"Therapeutics A. AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer: AffyImmune Therapeutics 2024 [Available from: https:\/\/affyimmune.com\/news\/affyimmune-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-aic100-in-recurrent-anaplastic-thyroid-cancer\/."},{"key":"4299_CR87","unstructured":"Therapeutics A. AffyImmune therapeutics\u2019 AIC100 granted fast track designation for treating thyroid cancer: AffyImmune Therapeutics; 2021 [Available from: https:\/\/affyimmune.com\/news\/affyimmune-therapeutics-aic100-granted-fast-track-designation-for-treating-thyroid-cancer\/."},{"issue":"1","key":"4299_CR88","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40164-022-00311-z","volume":"11","author":"J Ding","year":"2022","unstructured":"Ding J, Li D, Liu X, Hei H, Sun B, Zhou D, et al. Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer. Exp Hematol Oncol. 2022;11(1):59. https:\/\/doi.org\/10.1186\/s40164-022-00311-z.","journal-title":"Exp Hematol Oncol."},{"issue":"15","key":"4299_CR89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e14507","volume":"39","author":"L Xiao","year":"2021","unstructured":"Xiao L, Liu X, Zhou K, Liu Y, Huang Y, Pu C, et al. CoupledCAR technology for treating thyroid cancer. J Clin Oncol. 2021;39(15):e14507.","journal-title":"J Clin Oncol."},{"key":"4299_CR90","doi-asserted-by":"publisher","first-page":"1389971","DOI":"10.3389\/fimmu.2024.1389971","volume":"15","author":"BP Satapathy","year":"2024","unstructured":"Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, et al. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol. 2024;15:1389971. https:\/\/doi.org\/10.3389\/fimmu.2024.1389971.","journal-title":"Front Immunol."},{"key":"4299_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1493346","author":"W He","year":"2025","unstructured":"He W, Cui K, Farooq MA, Huang N, Zhu S, Jiang D, et al. TCR-T cell therapy for solid tumors: challenges and emerging solutions. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1493346.","journal-title":"Front Pharmacol"},{"key":"4299_CR92","unstructured":"Administration USFaD. FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma: U.S. Food and Drug Administration 2024 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma."},{"key":"4299_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.794183","volume":"11","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yan X, Zhang F, Zhang X, Tang F, Han Z, et al. TCR-T Immunotherapy: The Challenges and Solutions. Front Oncol. 2021;11:794183. https:\/\/doi.org\/10.3389\/fonc.2021.794183.","journal-title":"Front Oncol."},{"key":"4299_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.749973","author":"H Park","year":"2021","unstructured":"Park H, Park SY, Park J, Choe JH, Chung MK, Woo S-Y, et al. Prognostic value of preoperative serum calcitonin levels for predicting the recurrence of medullary thyroid carcinoma. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.749973.","journal-title":"Front Endocrinol."},{"key":"4299_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer Therapy With TCR-Engineered T Cells Current Strategies, Challenges, and Prospects. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.835762.","journal-title":"Front Immunol."},{"issue":"3","key":"4299_CR96","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/mt.2010.272","volume":"19","author":"MR Parkhurst","year":"2011","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620\u20136. https:\/\/doi.org\/10.1038\/mt.2010.272.","journal-title":"Mol Ther."},{"issue":"9","key":"4299_CR97","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/ct.2022;34.412-416","volume":"34","author":"MI Balcerek","year":"2022","unstructured":"Balcerek MI, Tey S-K, McLeod DSA. Adoptive cell therapy using genetically engineered T cells to target CEA, calcitonin, and RET M918T in medullary thyroid cancer cells. Clinical Thyroidology\u00ae. 2022;34(9):412\u20136. https:\/\/doi.org\/10.1089\/ct.2022;34.412-416.","journal-title":"Clinical Thyroidology\u00ae."},{"issue":"2","key":"4299_CR98","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3325\/cmj.2021.62.110","volume":"62","author":"S Mili\u0107evi\u0107","year":"2021","unstructured":"Mili\u0107evi\u0107 S, Bergant D, \u017dagar T, Peri\u0107 B. Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency. Croat Med J. 2021;62(2):110\u20139. https:\/\/doi.org\/10.3325\/cmj.2021.62.110.","journal-title":"Croat Med J."},{"issue":"1","key":"4299_CR99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s12022-021-09664-3","volume":"32","author":"JA Barletta","year":"2021","unstructured":"Barletta JA, Nos\u00e9 V, Sadow PM. Genomics and epigenomics of medullary thyroid carcinoma: from sporadic disease to familial manifestations. Endocr Pathol. 2021;32(1):35\u201343. https:\/\/doi.org\/10.1007\/s12022-021-09664-3.","journal-title":"Endocr Pathol."},{"key":"4299_CR100","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00622","volume":"8","author":"K Prabhash","year":"2024","unstructured":"Prabhash K, Saldanha E, Patil V, Bal M, Reddy PS, Sanjeev A, et al. RET alterations differentiate molecular profile of medullary thyroid cancer. JCO Precis Oncol. 2024;8:e2300622. https:\/\/doi.org\/10.1200\/po.23.00622.","journal-title":"JCO Precis Oncol."},{"key":"4299_CR101","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3389\/fimmu.2019.03045","volume":"10","author":"PG Kemps","year":"2019","unstructured":"Kemps PG, Zondag TC, Steenwijk EC, Andriessen Q, Borst J, Vloemans S, et al. Apparent lack of BRAF(V600E) Derived HLA class I presented neoantigens hampers neoplastic cell targeting by CD8(+) T cells in Langerhans cell histiocytosis. Front Immunol. 2019;10:3045. https:\/\/doi.org\/10.3389\/fimmu.2019.03045.","journal-title":"Front Immunol."},{"issue":"4","key":"4299_CR102","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1172\/jci98689","volume":"128","author":"JR Veatch","year":"2018","unstructured":"Veatch JR, Lee SM, Fitzgibbon M, Chow IT, Jesernig B, Schmitt T, et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest. 2018;128(4):1563\u20138. https:\/\/doi.org\/10.1172\/jci98689.","journal-title":"J Clin Invest."},{"issue":"4","key":"4299_CR103","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1172\/jci120386","volume":"128","author":"CS Hinrichs","year":"2018","unstructured":"Hinrichs CS. Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy. J Clin Invest. 2018;128(4):1261\u20133. https:\/\/doi.org\/10.1172\/jci120386.","journal-title":"J Clin Invest."},{"issue":"8","key":"4299_CR104","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","volume":"18","author":"GM Howell","year":"2013","unstructured":"Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18(8):926\u201332. https:\/\/doi.org\/10.1634\/theoncologist.2013-0072.","journal-title":"Oncologist."},{"issue":"1","key":"4299_CR105","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/cac2.12377","volume":"43","author":"H Yang","year":"2023","unstructured":"Yang H, Zhou X, Fu D, Le C, Wang J, Zhou Q, et al. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Cancer Commun. 2023;43(1):42\u201374. https:\/\/doi.org\/10.1002\/cac2.12377.","journal-title":"Cancer Commun."},{"key":"4299_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708949","author":"C Okafor","year":"2021","unstructured":"Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, et al. Update on targeted therapy in medullary thyroid cancer. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2021.708949.","journal-title":"Front Endocrinol"},{"issue":"7","key":"4299_CR107","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700. https:\/\/doi.org\/10.1126\/sciadv.adf3700.","journal-title":"Sci Adv."},{"issue":"8","key":"4299_CR108","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1089\/thy.2013.0680","volume":"24","author":"V Gunda","year":"2014","unstructured":"Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid. 2014;24(8):1241\u201350. https:\/\/doi.org\/10.1089\/thy.2013.0680.","journal-title":"Thyroid."},{"key":"4299_CR109","unstructured":"Clinicaltrials.gov. To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors: Clinicaltrials.gov 2017 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03159585."},{"issue":"8","key":"4299_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4(8):101133. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101133.","journal-title":"Cell Rep Med."},{"key":"4299_CR111","doi-asserted-by":"publisher","unstructured":"Gunda V, Cogdill AP, Bernasconi MJ, Wargo JA, Parangi S. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery. 2013;154(6):1456\u201362; discussion 62. https:\/\/doi.org\/10.1016\/j.surg.2013.07.009","DOI":"10.1016\/j.surg.2013.07.009"},{"issue":"1","key":"4299_CR112","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000566","volume":"4","author":"R Chen","year":"2025","unstructured":"Chen R, Johnson J, Rezazadeh A, Dudek AZ. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges. BMJ Oncol. 2025;4(1):e000566. https:\/\/doi.org\/10.1136\/bmjonc-2024-000566.","journal-title":"BMJ Oncol."},{"key":"4299_CR113","unstructured":"Administration USFaD. AMTAGVI: U.S. Food and Drug Administration 2024 [Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/amtagvi."},{"key":"4299_CR114","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf639","author":"B Garza","year":"2025","unstructured":"Garza B, Calhoun J, Norman P, Cline N, Kichula KM, Farias TDJ, et al. Tumor-infiltrating T lymphocytes recognize thyroid-specific and neo-antigens in follicular cell-derived thyroid cancers. J Clin Endocrinol Metab. 2025. https:\/\/doi.org\/10.1210\/clinem\/dgaf639.","journal-title":"J Clin Endocrinol Metab."},{"key":"4299_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114261","volume":"151","author":"A Jamal","year":"2025","unstructured":"Jamal A, Aldreiwish AD, Banawas SS, Alqurashi YE, Kamal MA, Ahmad F. The paths toward immunotherapy of esophageal cancer: an overview of clinical trials. Int Immunopharmacol. 2025;151:114261. https:\/\/doi.org\/10.1016\/j.intimp.2025.114261.","journal-title":"Int Immunopharmacol."},{"key":"4299_CR116","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008640","author":"V Albarr\u00e1n Fern\u00e1ndez","year":"2024","unstructured":"Albarr\u00e1n Fern\u00e1ndez V, Ballest\u00edn Mart\u00ednez P, Stoltenborg Granh\u00f8j J, Borch TH, Donia M, Svane Marie I. Biomarkers for response to TIL therapy: a comprehensive review. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2023-008640.","journal-title":"J Immunother Cancer."},{"issue":"6","key":"4299_CR117","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","volume":"31","author":"FJ Lowery","year":"2025","unstructured":"Lowery FJ, Goff SL, Gasmi B, Parkhurst MR, Ratnam NM, Halas HK, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nature Medicine. 2025;31(6):1994\u20132003. https:\/\/doi.org\/10.1038\/s41591-025-03627-5.","journal-title":"Nature Medicine."},{"issue":"8","key":"4299_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100702","volume":"6","author":"P Wiertsema","year":"2025","unstructured":"Wiertsema P, Tan YH, Haanen J, Seijkens TTP, Jedema I. Advances in TIL therapy: Expanding the horizons beyond melanoma. Med. 2025;6(8):100702. https:\/\/doi.org\/10.1016\/j.medj.2025.100702.","journal-title":"Med."},{"key":"4299_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105061","volume":"217","author":"TJ Qazi","year":"2026","unstructured":"Qazi TJ, Nunes AT, Xavier PLP, Fukumasu H. Oncolytic virotherapy: Molecular mechanisms, delivery strategies, and translational insights. Crit RevOncol\/Hematol. 2026;217:105061. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105061.","journal-title":"Crit RevOncol\/Hematol."},{"issue":"1","key":"4299_CR120","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy. 2023;8(1):156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","journal-title":"Signal Transduction and Targeted Therapy."},{"issue":"9","key":"4299_CR121","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1002\/cam4.2949","volume":"9","author":"Y Li","year":"2020","unstructured":"Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: The key to breaking the log jam? Cancer Med. 2020;9(9):2943\u201359. https:\/\/doi.org\/10.1002\/cam4.2949.","journal-title":"Cancer Med."},{"issue":"9","key":"4299_CR122","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1002\/hed.25769","volume":"41","author":"Y Miyagawa","year":"2019","unstructured":"Miyagawa Y, Araki K, Yamashita T, Tanaka S, Tanaka Y, Tomifuji M, et al. Induction of cell fusion\/apoptosis in anaplastic thyroid carcinoma in orthotopic mouse model by urokinase-specific oncolytic Sendai virus. Head Neck. 2019;41(9):2873\u201382. https:\/\/doi.org\/10.1002\/hed.25769.","journal-title":"Head Neck."},{"issue":"3","key":"4299_CR123","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.7314\/apjcp.2015.16.3.1241","volume":"16","author":"JN Wang","year":"2015","unstructured":"Wang JN, Xu LH, Zeng WG, Hu P, Rabkin SD, Liu RR. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus. Asian Pac J Cancer Prev. 2015;16(3):1241\u20135. https:\/\/doi.org\/10.7314\/apjcp.2015.16.3.1241.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"1","key":"4299_CR124","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-018-4522-3","volume":"18","author":"K Jiang","year":"2018","unstructured":"Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer. 2018;18(1):746. https:\/\/doi.org\/10.1186\/s12885-018-4522-3.","journal-title":"BMC Cancer."},{"issue":"10","key":"4299_CR125","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/cancers11101532","volume":"11","author":"AM Malfitano","year":"2019","unstructured":"Malfitano AM, Somma SD, Prevete N, Portella G. Virotherapy as a potential therapeutic approach for the treatment of aggressive thyroid cancer. Cancers (Basel). 2019;11(10):1532. https:\/\/doi.org\/10.3390\/cancers11101532.","journal-title":"Cancers (Basel)."},{"issue":"12","key":"4299_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"Q-W Zhang","year":"2012","unstructured":"Zhang Q-W, Liu L, Gong C-Y, Shi H-S, Zeng Y-H, Wang X-Z, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS one. 2012;7(12):e50946.","journal-title":"PloS one."},{"issue":"6","key":"4299_CR127","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369\u201382.","journal-title":"Nat Rev Immunol."},{"issue":"6657","key":"4299_CR128","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill R, Wirapati P, Messemaker M, Roh W, Zitti B, Duval F, et al. CXCL9: SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science. 2023;381(6657):515\u201324.","journal-title":"Science."},{"issue":"4","key":"4299_CR129","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","volume":"169","author":"Y Lavin","year":"2017","unstructured":"Lavin Y, Kobayashi S, Leader A, Amir E-AD, Elefant N, Bigenwald C, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750\u201365.","journal-title":"Cell."},{"issue":"8","key":"4299_CR130","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.immuni.2021.07.007","volume":"54","author":"K Mulder","year":"2021","unstructured":"Mulder K, Patel AA, Kong WT, Piot C, Halitzki E, Dunsmore G, et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity. 2021;54(8):1883-900.e5.","journal-title":"Immunity."},{"issue":"12","key":"4299_CR131","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0514","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhao J, Sun Y, Yang Z, Yang C, Zhu D. (2025) Single-cell RNA sequencing reveals tumor cell and immune cell variations associated with lymphatic metastasis in papillary thyroid cancer. Endocrine Connect. 2025;14(12):e250514. https:\/\/doi.org\/10.1530\/EC-25-0514.","journal-title":"Endocrine Connect."},{"issue":"11","key":"4299_CR132","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1158\/2326-6066.Cir-25-0159","volume":"13","author":"L Blanchard","year":"2025","unstructured":"Blanchard L, Mijacika A, Osorio JC. Targeting Myeloid Cells for Cancer Immunotherapy. Cancer Immunol Res. 2025;13(11):1700\u201315. https:\/\/doi.org\/10.1158\/2326-6066.Cir-25-0159.","journal-title":"Cancer Immunol Res."},{"issue":"4","key":"4299_CR133","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1677\/ERC-08-0036","volume":"15","author":"M Ryder","year":"2008","unstructured":"Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-related cancer. 2008;15(4):1069\u201374.","journal-title":"Endocrine-related cancer."},{"issue":"10","key":"4299_CR134","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1021\/acsptsci.5c00007","volume":"8","author":"SPR Naik GaRR","year":"2025","unstructured":"Naik GaRR SPR, Jadhav SR, Pokale R, Hedayat P, Datta D, et al. Role of colony stimulating factor 1 (CSF-1) and its receptor CSF1R: macrophage repolarization for glioblastoma treatment. ACS Pharmacology & Translational Science. 2025;8(10):3391\u2013410. https:\/\/doi.org\/10.1021\/acsptsci.5c00007.","journal-title":"ACS Pharmacology & Translational Science."},{"key":"4299_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530890","author":"Q Shang","year":"2025","unstructured":"Shang Q, Zhang P, Lei X, Du L, Qu B. Insights into CSF-1\/CSF-1R signaling: the role of macrophage in radiotherapy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1530890.","journal-title":"Front Immunol"},{"issue":"6","key":"4299_CR136","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/cancers9060068","volume":"9","author":"AR Dwyer","year":"2017","unstructured":"Dwyer AR, Greenland EL, Pixley FJ. Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers. 2017;9(6):68.","journal-title":"Cancers."},{"issue":"6","key":"4299_CR137","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tins.2016.03.005","volume":"39","author":"V Chitu","year":"2016","unstructured":"Chitu V, Gokhan \u015e, Nandi S, Mehler MF, Stanley ER. Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends in neurosciences. 2016;39(6):378\u201393.","journal-title":"Trends in neurosciences."},{"key":"4299_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107126","volume":"202","author":"Q Lv","year":"2024","unstructured":"Lv Q, Zhang Y, Gao W, Wang J, Hu Y, Yang H, et al. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacological Research. 2024;202:107126. https:\/\/doi.org\/10.1016\/j.phrs.2024.107126.","journal-title":"Pharmacological Research."},{"key":"4299_CR139","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1182\/blood-2025-5883","volume":"146","author":"G DeFranco","year":"2025","unstructured":"DeFranco G, Yun K, Manriquez Roman C, Feigin J, Olivier S, Hefazi Torghabeh M, et al. Targeting CSF1R to overcome myeloid cell suppression in CART therapy. Blood. 2025;146:5883. https:\/\/doi.org\/10.1182\/blood-2025-5883.","journal-title":"Blood."},{"issue":"11","key":"4299_CR140","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","volume":"3","author":"Y Nishiga","year":"2022","unstructured":"Nishiga Y, Drainas AP, Baron M, Bhattacharya D, Barkal AA, Ahrari Y, et al. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nature Cancer. 2022;3(11):1351\u201366. https:\/\/doi.org\/10.1038\/s43018-022-00456-0.","journal-title":"Nature Cancer."},{"issue":"19","key":"4299_CR141","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-24-0176","volume":"84","author":"B Li","year":"2024","unstructured":"Li B, Hao Y, He H, Fan Y, Ren B, Peng X, et al. CD47-SIRP\u03b1 blockade sensitizes head and neck squamous cell carcinoma to cetuximab by enhancing macrophage adhesion to cancer cells. Cancer Research. 2024;84(19):3189\u2013206. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0176.","journal-title":"Cancer Research."},{"issue":"7","key":"4299_CR142","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1089\/thy.2018.0555","volume":"29","author":"CM Sch\u00fcrch","year":"2019","unstructured":"Sch\u00fcrch CM, Roelli MA, Forster S, Wasmer MH, Br\u00fchl F, Maire RS, et al. Targeting CD47 in anaplastic thyroid carcinoma enhances tumor phagocytosis by macrophages and is a promising therapeutic strategy. Thyroid. 2019;29(7):979\u201392. https:\/\/doi.org\/10.1089\/thy.2018.0555.","journal-title":"Thyroid."},{"issue":"12","key":"4299_CR143","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nature reviews Drug discovery. 2018;17(12):887\u2013904.","journal-title":"Nature reviews Drug discovery."},{"issue":"10","key":"4299_CR144","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1541-7786.Mcr-13-0682","volume":"12","author":"S Joshi","year":"2014","unstructured":"Joshi S, Singh AR, Zulcic M, Durden DL. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1\u03b1 and HIF2\u03b1 stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res. 2014;12(10):1520\u201331. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-13-0682.","journal-title":"Mol Cancer Res."},{"key":"4299_CR145","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12249","author":"J Lv","year":"2021","unstructured":"Lv J, Liu C, Chen FK, Feng ZP, Jia L, Liu PJ, et al. M2-like tumour-associated macrophage-secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K\/AKT\/mTOR pathway. Mol Med Rep. 2021. https:\/\/doi.org\/10.3892\/mmr.2021.12249.","journal-title":"Mol Med Rep."},{"issue":"9","key":"4299_CR146","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1089\/thy.2017.0663","volume":"28","author":"F Borson-Chazot","year":"2018","unstructured":"Borson-Chazot F, Dantony E, Illouz F, Lopez J, Niccoli P, Wassermann J, et al. Effect of buparlisib, a pan-class I PI3K inhibitor, in refractory follicular and poorly differentiated thyroid cancer. Thyroid. 2018;28(9):1174\u20139. https:\/\/doi.org\/10.1089\/thy.2017.0663.","journal-title":"Thyroid."},{"issue":"15","key":"4299_CR147","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-12-3058","volume":"73","author":"I Le Mercier","year":"2013","unstructured":"Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer research. 2013;73(15):4629\u201340.","journal-title":"Cancer research."},{"issue":"1","key":"4299_CR148","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s40425-019-0724-8","volume":"7","author":"SR Mullins","year":"2019","unstructured":"Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, et al. Intratumoral immunotherapy with TLR7\/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J Immunother Cancer. 2019;7(1):244. https:\/\/doi.org\/10.1186\/s40425-019-0724-8.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"4299_CR149","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s12672-025-02888-3","volume":"16","author":"Y Metanat","year":"2025","unstructured":"Metanat Y, Sviridova M, Al-Nuaimi BN, Janbazi F, Jalali M, Ghalamkarpour N, et al. The role of non-coding RNAs in the regulation of cell death pathways in melanoma. Discov Oncol. 2025;16(1):1063. https:\/\/doi.org\/10.1007\/s12672-025-02888-3.","journal-title":"Discov Oncol."},{"issue":"12","key":"4299_CR150","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s00262-023-03549-6","volume":"72","author":"L Zhu","year":"2023","unstructured":"Zhu L, Li XJ, Gangadaran P, Jing X, Ahn BC. Tumor-associated macrophages as a potential therapeutic target in thyroid cancers. Cancer Immunol Immunother. 2023;72(12):3895\u2013917. https:\/\/doi.org\/10.1007\/s00262-023-03549-6.","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"4299_CR151","first-page":"3858","volume":"16","author":"H Liu","year":"2018","unstructured":"Liu H, Dong H, Jiang L, Li Z, Ma X. Bleomycin inhibits proliferation and induces apoptosis in TPC-1 cells through reversing M2-macrophages polarization. Oncology Letters. 2018;16(3):3858\u201366.","journal-title":"Oncology Letters."},{"key":"4299_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117925","volume":"256","author":"J Lv","year":"2020","unstructured":"Lv J, Chen F-K, Liu C, Liu P-J, Feng Z-P, Jia L, et al. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt\/\u03b2-catenin pathway. Life sciences. 2020;256:117925.","journal-title":"Life sciences."},{"issue":"1","key":"4299_CR153","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1186\/s12885-018-4522-3","volume":"18","author":"K Jiang","year":"2018","unstructured":"Jiang K, Song C, Kong L, Hu L, Lin G, Ye T, et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC cancer. 2018;18(1):746.","journal-title":"BMC cancer."},{"issue":"2","key":"4299_CR154","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.18632\/oncotarget.6430","volume":"7","author":"C Passaro","year":"2015","unstructured":"Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, Gigantino V, et al. The oncolytic virus dl922-947 reduces IL-8\/CXCL8 and MCP-1\/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma. Oncotarget. 2015;7(2):1500.","journal-title":"Oncotarget."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04299-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:22:36Z","timestamp":1787455356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":154,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4299"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04299-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Trial Registration Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}